Dimensional Fund Advisors
OPNT

Dimensional Fund Advisors’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Dimensional Fund Advisors’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,209
Closed -$2.03K – 3536
2022
Q4 		$2.03K Sell
100,209
-12,283
-11% -$188K ﹤0.01% 2723
2022
Q3 		$1.21M Sell
112,492
-14,800
-12% -$168K ﹤0.01% 2840
2022
Q2 		$1.53M Buy
127,292
+20,610
+19% +$332K ﹤0.01% 2821
2022
Q1 		$2.29M Buy
106,682
+40,031
+60% +$1.06M ﹤0.01% 2790
2021
Q4 		$2.24M Buy
66,651
+22,543
+51% +$628K ﹤0.01% 2818
2021
Q3 		$1.14M Buy
44,108
+22,346
+103% +$399K ﹤0.01% 3020
2021
Q2 		$301K Sell
21,762
-69
-0.3% -$853 ﹤0.01% 3256
2021
Q1 		$232K Buy
21,831
+2,253
+12% +$25.7K ﹤0.01% 3266
2020
Q4 		$158K Hold
19,578
– – ﹤0.01% 3250
2020
Q3 		$146K Buy
19,578
+5,644
+41% +$50.1K ﹤0.01% 3235
2020
Q2 		$125K Hold
13,934
– – ﹤0.01% 3257
2020
Q1 		$133K Buy
+13,934
New +$167K ﹤0.01% 3247

Dimensional Fund Advisors's OPNT Position: Q1 2023 in Review

Dimensional Fund Advisors sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 100,209 shares — an estimated $2.03K sold.

Dimensional Fund Advisors first reported a position in OPNT in Q1 2020 and held it in 12 quarters. The position peaked at $2.29M in Q1 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

  • Dimensional Fund Advisors reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 100,209 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $2.03K.
  • Dimensional Fund Advisors first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Dimensional Fund Advisors's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $2.29M in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Dimensional Fund Advisors's 13F filing for Q1 2023, filed 12 May 2023.